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Background: None of the current pleurodesing agents fulfil all the criteria for best pleural sclerosant. Therefore, the
search for the ideal agent for chemical pleurodesis still continues. The aim of the present study was to compare the
effectiveness of erythromycin, tetracycline, AerosilTM 200 (hydrophilic fumed amorphous silica), and erythromycin
plus AerosilTM 200 in producing pleurodesis in rats. In the present study, talc was not used as a pleurodesing agent
due to an unavailability of its sterile and pure form in Iran.
Methods: Overall, 75 adult male Spraque-Dawley rats were randomized to 5 treatment groups. Each group
received an intrapleural injection via 5 Fr Silastic tubes of one of the following sterile agents: 35mg/kg erythromycin
in 2 ml of saline, 35mg/kg tetracycline in 2 ml of saline, 35mg/kg AerosilTM 200 in 2ml of saline, erythromycin
(35mg/kg in 2 ml of saline) plus AerosilTM 200 (35mg/kg in 2 ml of saline), or 2 ml of saline as a control. The animals
were euthanized and necropsied 30 days after injection. The pleurae were assessed for macroscopic and
microscopic evidence of surrounding inflammation and fibrosis.
Results: The median macroscopic score in the AerosilTM 200 group was significantly higher than that in the
erythromycin group (P < 0.005). The median microscopic score in the erythromycin group was significantly lower
than that in the AerosilTM 200 and erythromycin plus AerosilTM 200 groups (P < 0.005). Furthermore, maximum and
minimum pleural fibrosis was observed in the erythromycin plus AerosilTM 200 and erythromycin groups,
respectively (P < 0.05).
Conclusion: This study suggests that AerosilTM 200 with or without erythromycin may be more potent pleurodesis
agent than erythromycin and tetracycline.
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Obliteration of the pleural space (pleurodesis) to prevent
recurrent pleural effusion (mostly malignant) or
pneumothorax is chiefly achieved through the use of
chemical pleural sclerosants [1]. The best pleural sclero-
sant should be safe, inexpensive, widely available, and
easily administered. However, none of the pleurodesing
agents including talc, the sclerosant of choice in clinical
practice, fulfil all these criteria [1-3]. Intrapleural* Correspondence: kghabili@gmail.com
5Physical Medicine and Rehabilitation Research Center, Tabriz University of
Medical Sciences, Tabriz, Iran
Full list of author information is available at the end of the article
© 2012 Hashemzadeh et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumadministration of the most preferred pleurodesing agent,
the talc, is believed to accompany with severe complica-
tions such as adult respiratory distress syndrome. On
the other hand, parenteral tetracycline which was once
the sclerosant agent of choice in clinical practice is no
longer commercially available [4]. In addition, intra-
pleural application of some antineoplastic agents such as
bleomycin is costly [5]. Therefore, the search for the
ideal agent for chemical pleurodesis still continues.
Silica is the common name for silicon dioxide (SiO2).
Silica may have a crystalline or a non-crystalline
(amorphous) structure. Among synthetic amorphous
silicas, pyrogenic (fumed) silica is widely used asCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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settling agents in liquid systems of coating, adhesives,
printing inks and cosmetics [6]. AerosilTM 200, a hydro-
philic fumed silica, is the most widely used form of the
amorphous silica. Silica-based materials have been of
great interest in chemical pleurodesis. Bioglass, a silica-
based biomaterial similar to the AerosilTM 200, has been
found as a pleurodesing agent as effective as talc [7,8].
The pleurodesing effect of bioglass, talc and AerosilTM
200 may be attributed to their major content, the silicon
dioxide. Interestingly, pulmonary changes following in-
halation of AerosilTM 200 have been reported in the lit-
erature [9,10]. However, pleurodesing effect of AerosilTM
200 has not been hitherto investigated. Therefore, the
aim of the present study was to compare the effective-
ness of erythromycin, tetracycline, AerosilTM 200, and
erythromycin plus AerosilTM 200 in producing pleurod-
esis in rats compared with saline control. We did not in-
vestigate talc as a sclerosing agent in the present study
due to an unavailability of its sterile and pure form.
Methods
Adult male Spraque-Dawley rats were used in this study
in accordance with the NIH Guide for the Care and
Use of Laboratory Animals and local institutional
guidelines for humane use of animals in research. The
animals were housed three to five per cage and were
provided with free access to compact food and water.
Their food consisted of all essential ingredients includ-
ing vitamins and minerals. The animals were kept
under constant laboratory conditions with respect to
humidity, illumination and temperature before and after
surgery [11,12].
Overall, 75 adult male Spraque-Dawley rats, weighing
220–250 g, were anesthetized with an intramuscular in-
jection of xylazine hydrochloride (5mg/kg) and ketamine
hydrochloride (35mg/kg). Under the sterile conditions, a
1-cm incision was made over the seventh rib in the pos-
terior axillary line on the rat’s right side, and a subcuta-
neous tunnel was extended to the fifth intercostal space.
A 5 Fr Silastic tube was inserted through the incision
and placed in the right pleural cavity. The rats were ran-
domly assigned to one of five intrapleural treatment
groups as follows: fifteen rats received erythromycin
ethylsuccinate (35mg/kg) in 2 ml of saline (0.9% NaCl);
fifteen animals were given tetracycline (35mg/kg) in 2
ml of saline; fifteen rats were given sterile AerosilTM 200
(35mg/kg) in 2 ml of saline; fifteen animals received
erythromycin ethylsuccinate (35mg/kg in 2 ml of saline)
plus sterile AerosilTM 200 (35mg/kg in 2 ml of saline);
and fifteen control animals received 2 ml of normal sa-
line. All the sclerosing agents were given sterile. These
agents were instilled into the tube and flushed with air,
and the animals were rotated to assure dispersion to theentire pleural surface. The control group received nor-
mal saline in a similar approach. All residual air was
aspirated from the pleural space. After a perioperative
chest radiograph demonstrated a fully expanded lung,
the tube was removed, and the incision was closed. All
animals were left to heal with both lungs expanded.
All animals in the experimental and control groups
were euthanized on 30th postoperative day by intraven-
ous Beuthanasia-D, a pentobarbital/phenytoin commer-
cial euthanasia solution. The thorax was removed en
bloc. Lungs were fully expanded by instilling 10% forma-
lin into trachea. After tracheal injection, the entire
thorax was submerged in 10% neutral buffered formalin
for 48 hours. Thereafter, a veterinary pathologist, blinded
to the treatment group, performed thoracic necropsy.
On macroscopic and gross observations, pleurodesis was
graded as: 0 = normal pleura, 1 = multifocal fibrosis, 2 =
diffuse adhesions and 3 = complete obliteration [2,13].
For microscopic evaluation, tissue sections from the lung
and pleura were prepared and stained with hematoxylin
and eosin (HE) and Masson’s trichrome. Light micro-
scopic assessment of the sections was performed by a
pathologist blinded to the study protocol. The slides
were graded for inflammation/cellularity and scored
using the following system: 0 (absence of cellularity and
neovascularisation), 1 (mild cellularity and neovasculari-
sation), 2 (moderate cellularity and neovascularisation),
and 3 (severe cellularity and neovascularisation) [14].
Moreover, microscopic fibrosis was defined based on the
similar grading system as absent (0), mild (1), moderate
(2), and severe (3).
Data were presented as mean = standard deviation
(SD), median or percentage. Statistical analysis was per-
formed with SPSS for windows version 13.0. The chi-
square test (P < 0.05) was used to compare the incidence
of pleural fibrosis, pleural cellularity and neovasculariza-
tion, and pleural adhesions among the groups. The
Kruskal-Wallis test (P < 0.05) was used to compare the
median macroscopic, microscopic, cellularity, neovascu-
larization and fibrosis scores among the groups. There-
after, comparisons between two groups were conducted
with the Mann–Whitney ranking test. In order to avoid
accumulation of errors due to multiple comparisons, the
significance level was modified dividing it (P < 0.05) by
the number of comparisons made (Bonferroni correc-
tion) with P < 0.005 considered as significant.
Results
Gross necropsy
No deaths occurred in any of the studied groups. At
30 days, the normal saline (control) group produced
no considerable adhesions or pleurodesis on gross ob-
servation. In the erythromycin group, adhesions were
grossly visible between the parietal and the visceral
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200 group had the greatest number of rats with pleural
adhesions (93.3%), there was no significant difference
between the studied groups in this regard (P > 0.05,
Table 1). Furthermore, AerosilTM 200 and erythromycin
plus AerosilTM 200 groups showed higher numbers of
diffuse adhesion (score 2) and complete obliteration
(score 3) on gross observation (P > 0.05, Figure 1). The
median macroscopic score in the AerosilTM 200 group
was significantly higher than that in the erythromycin
group (P < 0.005, Bonferroni-corrected Mann–Whitney
U test, Table 2).
Histopathology
The normal saline (control) group produced no consid-
erable cellularity, neovascularisation, or fibrosis on
microscopic observation at 30 days. Microscopically, all
the erythromycin-treated rats exhibited inflammation,
while only 40% (6/15) had pleural fibrosis. Pleural fibro-
sis was significantly lower in the erythromycin group
compared with other treatment groups (P = 0.007,
Table 1). Moreover, all rats in the treatment groups
showed pleural inflammation (Table 1). In addition,
pleural fibrosis was significantly higher in the erythro-
mycin plus AerosilTM 200 group compared with other
treatment groups (P = 0.02, Table 1).
Figure 2 illustrates the number of each microscopic
(inflammation/cellularity) score in the studied treatment
groups. Accordingly, none of the treatment groups had
absence of cellularity and neovascularisation in the
microscopic assessment (score 0). Furthermore, Aero-
silTM 200 and erythromycin plus AerosilTM 200 groups
showed higher numbers of severe cellularity and
neovascularisation (score 3) on microscopic observation
(P > 0.05, Figure 2). Overall, the median microscopic
score in the erythromycin group was significantly lower
than that in the AerosilTM 200 and erythromycin plus
AerosilTM 200 groups (P < 0.005, Bonferroni-corrected
Mann–Whitney U test, Table 2). On the other hand, the
AerosilTM 200 group showed higher cellularity score than
erythromycin and tetracycline groups (P < 0.005,
Bonferroni-corrected Mann–Whitney U test, Table 2).
In addition, neovascularization and fibrosis scores in
erythromycin plus AerosilTM 200 group were significantly
higher than those in the erythromycin group (P < 0.005,
Bonferroni-corrected Mann–Whitney U test, Table 2).Table 1 Treatment-related microscopic and macroscopic findi
Saline (n = 15) Erythromycin (n = 15) Tetracycline
Pleural fibrosis 0 (0) 6 (40%)* 11 (73.
Pleural inflammation 0 (0) 15 (100%) 15 (100
Pleural adhesions 0 (0) 10 (66.6%) 11 (73.
Erythromycin treatment and erythromycin plus Aerosil
TM
200 treatment significantly
respectively (*P = 0.007; **P = 0.02, Chi-square test).Discussion
This rat model evaluated the effectiveness of erythro-
mycin, tetracycline, AerosilTM 200 and erythromycin plus
AerosilTM 200 as pleural sclerosing agents. This study
demonstrated that AerosilTM 200 with or without
erythromycin was more potent pleurodesis agent both
grossly and microscopically. To the best of our know-
ledge, the present study is the first investigation to study
the pleurodesing effect of intrapleural AerosilTM 200.
However, there are a few studies on the health effects of
AerosilTM 200. In an animal investigation by Reuzel and
colleagues, subchronic inhalation of AerosilTM 200
induced the most severe changes in the lungs among
other examined amorphous silicas [9]. In another study,
Johnston et al. observed reversible inflammatory
responses in bronchoalveolar lavage after inhalation of
amorphous silica (AerosilTM 200), while no mutagenic
events were noted [10]. Likewise, recent experimental
studies confirmed the pulmonary fibrogenetic effects of
amorphous silica such as AerosilTM 200 [15-17].
Chemical pleurodesis with silica-containing materials
has been of utmost interest. Yeginsu and colleagues
found that bioglass was as effective as talc in terms of
pleurodesis [7,8]. It is believed that silicon dioxide or sil-
ica contributes to the pleurodesing effect of bioglass, talc
and AerosilTM 200. Silicon dioxide or silica exposure has
been found to cause lung damage through direct cyto-
toxicity, generation of reactive oxygen species from al-
veolar macrophages, and stimulation of secretion of
inflammatory cytokines, chemokines, and fibrogenic fac-
tors from alveolar macrophages and/or epithelial cells
[7,18]. Although similar mechanism might be deemed
for the AerosilTM 200 particles, further investigations
orchestrated on the mechanisms of AerosilTM 200-
induced pleurodesis are recommended.
Both in gross and microscopic assessments, erythro-
mycin was less potent pleurodesis agent than the Aero-
silTM 200. This finding is in contrast to that of the
previous experimental study indicating that erythro-
mycin was an ideal pleural sclerosing agent, compared
with talc, doxycycline and diazepam [2]. Moreover, in a
recent clinical study by Balassoulis et al., erythromycin
was found as an effective and safe pleurodesing agent in
patients with recurrent malignant pleural effusions [19].
However, we do not have an explanation for such a dif-
ference in the pleurodesing effect of erythromycin.ngs, n (%)
(n = 15) AerosilTM 200 (n = 15) Erythromycin + AerosilTM 200 (n = 15)
3%) 11 (73.3%) 14 (93.3%)**
%) 15 (100%) 15 (100%)
3%) 14 (93.3%) 13 (86.6%)













Saline Erythromycin Tetracycline Aerosil Erythromycin + Aerosil
Figure 1 Frequency of macroscopic scores in the treatment groups. Microscopic scores were 0 = normal pleura, 1 =multifocal fibrosis,
2 = diffuse adhesions and 3 = complete obliteration.
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pleurodesing agents in the present study. This finding is
compatible with that of the previous reports; fibrin tissue
adhesive [20], talc [21], and mitoxantrone were found as
more effective sclerosing agents than tetracycline for
pleurodesis [22]. In contrast, Vargas and colleagues
found that tetracycline, rather than bleomycin and
Corynebacterium parvum, was more potent pleurodes-
ing agent in a rabbit model [23,24]. In a systematic re-
view, tetracycline was reported to be associated with
more recurrences when compared to talc [3]. The avail-
able clinical evidence supports the use of talc as the
sclerosant of choice rather than other sclerosants (tetra-
cycline, bleomycin, or mustine) [1].
This study has certain limitations. We did not investi-
gate talc as a sclerosing agent in the present study. The
rationale behind this exclusion was the lack of sterile
and pure talc in Iran. Moreover, other routinely usedTable 2 Treatment-related macroscopic, microscopic, cellulari







Macroscopic score 0 ± 0 (0) 1 ± 0.9 (1) 1.2 ± 1 (1)
Microscopic score 0 ± 0 (0) 1.2 ± 0.4 (1) 1.5 ± 0.5 (1
Cellularity score 0 ± 0 (0) 1.2 ± 0.4 (1) 1.1 ± 0.4 (1
Neovascularization score 0 ± 0 (0) 0.8 ± 0.4 (1) 1.4 ± 0.5 (1
Fibrosis score 0 ± 0 (0) 0.4 ± 0.5 (0) 1.3 ± 0.9 (1
a All other treatment groups significantly differed from the normal saline group (P <
b Macroscopic, microscopic and cellularity scores in erythromycin group were signif
Mann–Whitney U test).
c Cellularity score in tetracycline group was significantly different from Aerosil
TM
200
d Microscopic, neovascularization and fibrosis scores in erythromycin plus Aerosil
TM
test as above).pleurodesing agents such as bleomycin and parenteral
doxycycline were not available due to their high costs.
Therefore, further studies are recommended to be
orchestrated in order to investigate the probable advan-
tage of the AerosilTM 200 over the most commonly used
pleurodesis agents such as sterile and pure talc in terms
of efficacy, safety, rapidity of action, mechanism of ac-
tion or cost. In addition, one may consider the rabbit
model as generally more established method for experi-
mental pleurodesis. However, there are a number of ex-
perimental studies of pleurodesis on the rats [20,25-27].
Only single dose of 35 mg/kg was studied for each scler-
osant, and different doses might have resulted in more
favorable responses. However, the applied treatment
dosages were based on those of the previous studies. Fu-
ture studies with larger doses of erythromycin and tetra-
cycline may achieve higher response rates. Furthermore,
distant sequelae of the studied pleurodesing agents inty, neovascularization and fibrosis scores,
e c AerosilTM 200
(n = 15)
Erythromycin + AerosilTM 200 d
(n = 15)
P value
2.3 ± 1 (3) 1.9 ± 1 (1) <0.001
) 2.1 ± 0.7 (2) 2.1 ± 0.7 (2) <0.001
) 2 ± 0.7 (2) 1.7 ± 0.9 (1) <0.001
) 1.1 ± 1.1 (1) 2.1 ± 0.8 (2) <0.001
) 1.5 ± 1.2 (1) 1.1 ± 0.5 (1) <0.001
0.001, Kruskal-Wallis test).
icantly different from Aerosil
TM
200 group (P < 0.005, Bonferroni-corrected
group (P < 0.005, test as above).













Saline Erythromycin Tetracycline Aerosil Erythromycin + Aerosil
Figure 2 Frequency of microscopic (inflammation/cellularity) scores in the treatment groups. Microscopic (inflammation/cellularity) scores
were 0 = absence of cellularity and neovascularisation, 1 =mild cellularity and neovascularisation, 2 =moderate cellularity and neovascularisation,
and 3 = severe cellularity and neovascularisation.
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systemic effects were not evaluated. Liver enzyme tests,
histopathological assessment of the contralateral lung
and the liver, and serum and tissue angiotensin-
converting enzyme could have provided precious infor-
mation regarding the toxicity of the studied pleurodesing
agents, in particular the AerosilTM 200. In addition, grad-
ing of the pleurodesis immediately after sacrificing the
animals while the tissues were fresh and soft might have
yielded to different results. The formalin exposure makes
the tissues firm and shrunk, resulting in difficult evalu-
ation of the pleural adhesions [8].
Conclusion
In conclusion, this preliminary study suggests that
AerosilTM 200 with or without erythromycin may be
more potent pleurodesis agent than erythromycin and
tetracycline. As superiority between AerosilTM 200 alone
and AerosilTM 200 plus erythromycin could not be
determined with the results of the present study, fur-
ther cost-effective investigations targeting at the distant
sequelae of these treatments are required.
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